Immunotherapies have been increasingly successful with their efficacy as monotherapy regimens now well established. The aim now is raising the response rate and show effects in a wider range of patients. For that, the focus shifted towards combination regimens, combining immunotherapies with other immunotherapies or standard therapies. The challenge is to identify which combination works, in what tumor indications and specifically in which population. The aim of this research was to anticipate promising developments and to identify trends.